Tvardi Therapeutics (TVRD) Stock Chart & Stock Price History $24.67 -0.07 (-0.28%) As of 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Tvardi Therapeutics Stock Price Performance The Tvardi Therapeutics (TVRD) stock chart highlights key performance trends across multiple timeframes. In the past month, the stock has increased 0.24%, reflecting recent market activity. As of the latest close, Tvardi Therapeutics traded at $24.74 with a market cap of $231.57 million and volume of 10,712 shares. Receive TVRD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+3.70%1 Month Performance+0.24% TVRD Stock Chart for Tuesday, August, 19, 2025 TVRD Chart by TradingView Tvardi Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/18/2025$24.00$24.74+3.08%$25.34$23.7910,712 shs$231.57 million08/15/2025$23.79$24.00+0.88%$24.62$23.7912,588 shs$224.64 million08/14/2025$23.74$23.79+0.21%$24.05$22.9111,668 shs$222.67 million08/13/2025$23.60$23.74+0.59%$24.55$23.7017,500 shs$222.23 million08/12/2025$24.13$23.60-2.20%$25.00$23.4622,159 shs$220.90 million08/11/2025$23.92$24.13+0.88%$24.75$22.7432,952 shs$225.86 million08/08/2025$23.12$23.92+3.46%$24.89$22.4014,114 shs$223.89 million08/07/2025$24.14$23.12-4.23%$24.34$22.8413,990 shs$216.43 million08/06/2025$25.99$24.14-7.12%$25.49$23.7822,564 shs$225.95 million08/05/2025$26.34$25.99-1.33%$26.69$24.8844,015 shs$243.27 million Get the Latest News and Ratings for TVRD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/04/2025$26.20$26.34+0.53%$27.76$25.4636,147 shs$246.57 million08/01/2025$25.96$26.20+0.92%$26.45$25.2722,180 shs$245.26 million07/31/2025$25.69$25.96+1.05%$26.55$25.6131,876 shs$242.99 million07/30/2025$25.98$25.69-1.12%$27.05$25.1119,303 shs$240.46 million07/29/2025$24.87$25.98+4.46%$26.62$24.3047,779 shs$243.20 million07/28/2025$26.52$24.87-6.22%$26.31$24.8015,664 shs$232.78 million07/25/2025$27.29$26.52-2.82%$27.72$26.0214,520 shs$248.23 million07/24/2025$28.64$27.29-4.71%$28.54$25.9122,924 shs$255.43 million07/23/2025$25.37$28.64+12.89%$28.75$25.5050,788 shs$268.07 million07/22/2025$25.88$25.37-1.97%$26.07$24.4251,369 shs$237.46 million07/21/2025$24.61$25.88+5.16%$25.97$24.4835,463 shs$242.24 million07/18/2025$23.98$24.61+2.63%$25.55$24.0128,374 shs$230.35 million Related Companies Iovance Biotherapeutics Stock Price Chart Akebia Therapeutics Stock Price Chart Anavex Life Sciences Stock Price Chart uniQure Stock Price Chart Immunome Stock Price Chart Sana Biotechnology Stock Price Chart Nurix Therapeutics Stock Price Chart atai Life Sciences Stock Price Chart Gyre Therapeutics Stock Price Chart Pharming Group Stock Price Chart Receive TVRD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:TVRD) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access